Figure 3. Evaluation of 68Ga-HZ20 in the rhACE2 intratumoral model based on A549 cells. (A) PET imaging at 60 min after68Ga-HZ20 injection following intratumoral injection of different doses of rhACE2. The white box with a dashed line indicates the tumor and the injection site of rhACE2 (K, B stands for kidney and bladder). (B) Comparison of SUVmax in the tumors in Figure 3A and Figure S6. (C) The ratio of tumor to muscle SUVmax at different time points following 68Ga-HZ20 injection. (D) Ex vivo PET imaging of tumor tissue treated with different doses of rhACE2. (E) Comparison of % ID/g in tumor tissue treated with different doses of rhACE2. (F) Correlation analysis between SUVmax and rhACE2 doses at 30 min after injection. (G) Western blot of rhACE2 at the injection site.